TNBC accounts for approximately 15-20% of breast cancer cases and is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 receptor expression, which severely limits treatment options. The newly identified compound DHL-11 emerges as a targeted agent exhibiting robust antitumor activity, selectively striking at a molecular vulnerability in TNBC cells. This compound represents a novel class of naturally derived prieurianin-type limonoids, a group of triterpenoids known for diverse biological activities, yet unexplored in this oncological context until now.

The research delves into the biochemical underpinnings of how DHL-11 exerts its anticancer effects. Experimental evidence demonstrates that DHL-11 effectively curtails TNBC cell proliferation and impairs their migratory capabilities, crucial factors in tumor growth and metastasis. The compound induces arrest of TNBC cells in the G2/M phase of the cell cycle, a checkpoint that ensures DNA integrity before mitosis, thereby halting cellular division. Further, DHL-11 promotes apoptotic cell death, amplifying cytotoxic effects against cancerous cells.

A particularly compelling feature of DHL-11 is its ability to elevate intracellular reactive oxygen species (ROS) levels. ROS are chemically reactive molecules that, in excess, induce oxidative stress, damaging DNA and other cellular components. The study observes that DHL-11 triggers a surge in ROS accumulation within TNBC cells, precipitating DNA damage that undermines cellular survival and replication processes. This mechanistic insight places oxidative stress induction at the center of DHL-11’s anticancer activity.

At the molecular level, DHL-11 targets inosine monophosphate dehydrogenase 2 (IMPDH2), an essential enzyme involved in guanine nucleotide biosynthesis. IMPDH2 catalyzes the rate-limiting step of converting inosine monophosphate (IMP) to xanthosine monophosphate (XMP), ultimately leading to guanine nucleotide triphosphate (GTP) production, critical for DNA and RNA synthesis. The study reveals that DHL-11 binds specifically to a non-catalytic pocket on IMPDH2, a novel binding site distinct from the enzyme’s active center.

Intriguingly, this binding disrupts the interaction between IMPDH2 and another protein, FANCI (Fanconi anemia complementary group I), which is known for its role in DNA repair. The dissociation destabilizes IMPDH2, triggering its degradation via the cellular protein degradation machinery. Loss of IMPDH2 function drastically reduces guanine synthesis, depleting nucleotide pools required for tumor cell proliferation and increasing susceptibility to DNA replication stress.

The degradation of IMPDH2 caused by DHL-11 culminates in a cascade of cellular disturbances. Guanine scarcity contributes to impediments in DNA replication fidelity, while concurrent ROS accumulation exacerbates DNA damage. This dual assault on cancer cell genomic maintenance mechanisms leads to replication stress and ultimately to apoptosis of TNBC cells. The therapeutic implications of these findings highlight a multifaceted approach leveraging metabolic disruption and oxidative damage.

Importantly, the translational potential of DHL-11 is underscored by its efficacy in patient-derived breast cancer organoids characterized by high IMPDH2 expression. These 3D organoid models recapitulate patient tumor architecture and heterogeneity, rendering them highly predictive for clinical outcomes. DHL-11 markedly suppressed the growth of these organoids, providing preclinical evidence supporting its development as a viable anti-TNBC agent.

In vivo validation was further achieved in TNBC xenograft models, where systemic administration of DHL-11 significantly inhibited tumor growth and metastasis. These animal studies not only confirmed the compound’s antitumor activity but also demonstrated an encouraging biosafety profile, with no significant adverse effects observed. This favorable therapeutic index enhances DHL-11’s appeal as a drug candidate worthy of further clinical investigation.

Collectively, these findings position DHL-11 as a pioneering IMPDH2 degrader with unique mechanisms disrupting tumor nucleotide metabolism and DNA repair pathways. This dual mechanism induces cytotoxicity in cancer cells exhibiting elevated IMPDH2 expression, particularly the notoriously treatment-resistant TNBC subtype. Such targeted biochemical interference may represent a new frontier in precision oncology.

This landmark study not only enriches the pharmacological landscape with a novel natural compound but also sets the stage for future research exploring prieurianin-type limonoids as a source of anticancer therapeutics. The compelling data encourage expansion into clinical trials, potentially offering renewed hope for patients battling triple-negative breast cancer, which has historically lacked effective targeted drugs.

The promising capacity for DHL-11 to selectively degrade IMPDH2 and induce lethal DNA damage suggests a broader application scope beyond TNBC, possibly extending to other malignancies reliant on guanine nucleotide biosynthesis. Continued exploration of this compound’s mechanism may unravel further insights into the intricate interplay between metabolic enzymes and DNA repair in cancer pathophysiology.

In essence, DHL-11 embodies a molecular breakthrough by leveraging targeted enzyme degradation and oxidative stress augmentation to undermine TNBC cell survival. This innovative approach exemplifies the fusion of natural product discovery and molecular oncology, underscoring the potential of plant-derived compounds in addressing formidable cancer subtypes like triple-negative breast cancer.

Subject of Research: Investigation of DHL-11, a prieurianin-type limonoid from Munronia henryi, as a targeted IMPDH2 degrader for the treatment of triple-negative breast cancer.

Article Title: DHL-11, a novel prieurianin-type limonoid isolated from Munronia henryi, targeting IMPDH2 to inhibit triple-negative breast cancer.

News Publication Date: Not explicitly provided (article in Acta Pharmaceutica Sinica B, Volume 16, Issue 1, 2026).

Web References:

• DOI Link: http://dx.doi.org/10.1016/j.apsb.2025.10.031
• Journal Site: https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b

Keywords: Limonoids, DHL-11, Triple-negative breast cancer (TNBC), Reactive oxygen species (ROS), DNA damage, IMPDH2, Guanine synthesis, FANCI, Apoptosis, Cell cycle arrest, Metastasis, Enzyme degradation.

Fibrosarcoma is a type of cancer that arises from fibrous connective tissue, commonly presenting a formidable challenge to oncologists due to its tendency to metastasize aggressively. Historically, treatment options have been limited, often encompassing surgery, radiation, and chemotherapy, each with varying degrees of efficacy and significant side effects. Thus, the search for new agents that can induce cancer cell death without adversely affecting surrounding healthy tissue is more essential than ever. In this context, the study conducted by Yildirim and Bakar-Ates holds promise for a breakthrough in the therapeutic landscape of fibrosarcoma.

The innovative approach of the study focused on elucidating the molecular pathways affected by nafamostat mesylate. The researchers employed a variety of in vitro techniques to assess its impact on fibrosarcoma cell lines. Remarkably, the study unveiled that nafamostat mesylate triggers mitochondrial apoptosis—a process that causes programmed cell death through mitochondrial pathways. This is particularly notable, as mitochondrial apoptosis is a highly regulated and complex process that many anticancer drugs struggle to effectively exploit. The implications of these findings can be extensive, providing vital data on how nafamostat mesylate might navigate the hurdles faced by various cancer treatments.

In addition to highlighting the compound’s capacity to induce apoptosis, the investigation also revealed a critical link between nafamostat mesylate treatment and the suppression of matrix metalloproteinase (MMP) gene expression, specifically MMP-2 and MMP-9. These enzymes are often implicated in cancer metastasis as they facilitate the degradation of extracellular matrix components, allowing cancer cells to invade surrounding tissues. By Downregulating MMP-2 and MMP-9 expression, nafamostat mesylate could significantly impede the metastatic potential of fibrosarcoma, thus reinforcing the rationale for its clinical application.

The ability of nafamostat mesylate to target both the apoptotic machinery and metastasis markers unveils its multifaceted anticancer activity, a hallmark of effective cancer therapeutics. As an established and well-tolerated compound, its repurposing could potentially speed up the transition from laboratory to clinical settings, minimizing delays associated with the development of novel drugs. This aspect is particularly important considering the urgent medical need to improve patient outcomes in fibrosarcoma, where prognosis remains poor, and options are limited.

Furthermore, the findings from this study mark the first evidence of nafamostat mesylate’s effects on mitochondrial pathways and its regulatory influence on MMP expression in fibrosarcoma, underlining the novelty and significance of the research. The connection between drug efficacy and the biochemical responses within the mitochondria emphasizes the importance of targeting energy-producing organelles when designing cancer therapies. Understanding these interactions at a cellular level can provide a comprehensive blueprint for developing more effective treatment regimens.

As the landscape of cancer treatment continues to evolve, the relevance of finding existing drugs with anticancer properties cannot be overstated. The research not only contributes to the growing body of literature on nafamostat mesylate but also emphasizes the potential of drug repurposing as a viable strategy to expedite patient access to effective therapies. The study’s implications stretch beyond fibrosarcoma, as the mechanisms delineated could inform research into other malignancies characterized by similar apoptotic and metastatic dilemmas.

The exploration of nafamostat mesylate’s role in cancer therapy also encourages future research endeavors aimed at understanding its effects in combination with other treatment modalities. There exists a tantalizing possibility that, when used in conjunction with chemotherapy or immunotherapy, tafamostat mesylate could enhance the overall therapeutic efficacy while minimizing the likelihood of resistance development—a common pitfall in cancer treatment.

To truly understand the impact of nafamostat mesylate in a clinical context, subsequent clinical trials will be essential. While preclinical findings provide a solid foundation, rigorous evaluation of its safety and effectiveness through well-designed clinical studies is vital before it can be integrated into standard care protocols. A comprehensive clinical assessment would not only validate the preclinical results but also reveal the broader implications of nafamostat mesylate in oncology.

In conclusion, the recent investigation into nafamostat mesylate reveals critical insights into its multifaceted anticancer activity against human fibrosarcoma, illuminating pathways of mitochondrial apoptosis and MMP suppression. The innovative findings reinforce the potential for existing drugs to be repurposed for cancer treatment, offering a beacon of hope for patients with malignancies that are difficult to treat. As researchers continue to unravel the complexities of cancer biology, compounds like nafamostat mesylate may play an increasingly pivotal role in advancing therapeutic strategies that are both effective and patient-friendly.

The implications of this research go beyond the immediate findings and open doors to a more nuanced understanding of cancer treatment. By bridging the gap between basic science and clinical application, researchers can aspire to significantly impact patient care. The journey from bench to bedside is often fraught with challenges. However, as demonstrated by the promising results surrounding nafamostat mesylate, such efforts are essential for fostering hope in the relentless battle against cancer.

Subject of Research: Nafamostat mesylate and its antitumor effects in human fibrosarcoma.

Article Title: Multifaceted anticancer activity of nafamostat mesylate in human fibrosarcoma: first evidence of mitochondrial apoptosis and suppressed MMP-2/-9 mRNA expression.

Article References:

Yildirim, C., Bakar-Ates, F. Multifaceted anticancer activity of nafamostat mesylate in human fibrosarcoma: first evidence of mitochondrial apoptosis and suppressed MMP-2/-9 mRNA expression.
BMC Pharmacol Toxicol 26, 194 (2025). https://doi.org/10.1186/s40360-025-01038-3

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s40360-025-01038-3

Keywords: Nafamostat mesylate, anticancer activity, mitochondrial apoptosis, fibrosarcoma, MMP-2, MMP-9, drug repurposing, cancer therapy.

The concept of mining fungi for medicinal compounds is not new—antibiotics like penicillin owe their origins to fungal metabolites—but the curative promise of RiPPs in fungi has remained largely untapped until now. Fungal RiPPs present a unique biosynthetic challenge due to their complex synthesis pathways, distinctly different from the well-studied bacterial counterparts. These peptides are synthesized directly by ribosomes before undergoing intricate post-translational modifications that bestow them with enhanced pharmaceutical properties. The rarity and difficulty in purifying these molecules have historically hampered their integration into drug discovery, yet the meticulous work by this research team breaks new ground by uncovering a previously unknown assembly of RiPPs, termed asperigimycins, characterized by their exceptional heptacyclic benzofuranoindoline frameworks.

A. flavus, apart from its historical notoriety, harbors gene clusters previously elusive to researchers. Employing a combined approach of gene knockout experiments and mass spectrometry-based metabolic profiling, the team deciphered the genetic underpinnings responsible for RiPP biosynthesis in the fungus. This strategy allowed them to conclusively link specific proteins to the production of bioactive asperigimycins, while demonstrating that disabling these genes eradicated the signature chemical markers of these compounds in fungal cultures. Such integration of genetic and metabolomic data not only illuminated fungal RiPP biosynthesis but also set a methodological precedent for identifying novel natural products across other pathogenic or symbiotic fungi.

The purified asperigimycins exhibited remarkable anticancer activity in vitro, focusing primarily on leukemia cell lines. Two of the four distinct asperigimycin variants revealed significant cytotoxic effects without any chemical modification, underscoring their potential as lead compounds in drug development. Intriguingly, one variant modified with a lipid moiety analogous to components found in royal jelly—a nutrient-rich secretion essential for bee larvae development—demonstrated comparable efficacy to cytarabine and daunorubicin, both cornerstone drugs in leukemia treatment. This lipid conjugation not only increased potency but also highlighted a novel avenue to enhance cellular uptake and bioavailability of cyclic peptides, traditionally hindered by their large, complex structures.

Delving deeper into the mechanisms governing cellular entry, the researchers pinpointed a gene named SLC46A3 within leukemia cells that plays a pivotal role in facilitating the transport of asperigimycins from lysosomal compartments into the cytosol. This transporter’s gating function appears critical for the compounds’ therapeutic effects, suggesting that lipid modification may optimize the interaction with SLC46A3, thereby amplifying intracellular concentrations of the bioactive molecules. This insight unveils a new paradigm in drug design where modifying natural product structures to exploit endogenous trafficking pathways could revolutionize the delivery efficiency of cyclic peptide-based drugs.

Further mechanistic investigations revealed that asperigimycins exert their anticancer effects through disruption of microtubule dynamics, an essential process for mitotic cell division. By binding to components involved in microtubule polymerization, these fungal RiPPs selectively inhibit the proliferation of leukemia cells, sparing other cancer types and non-cancerous cells alike. This specificity is a breakthrough in targeted therapy, minimizing off-target effects and toxicity—a significant challenge with existing chemotherapy agents. Such precision medicine, built on natural product scaffolds, promises to enhance patient outcomes while reducing side effects.

Another compelling aspect of this discovery is the fungus’s restriction of asperigimycins’ activity spectrum, which includes no observed antibacterial or antifungal effects. This delineation hints at a sophisticated biological interaction, where these molecules have evolved to target specific eukaryotic cellular pathways, possibly as a defense mechanism in natural environments. Understanding this evolutionary context enriches drug discovery by providing clues on molecular specificity and guiding structural modification strategies to fine-tune pharmacological targets.

The potential ripple effects of this study extend beyond A. flavus. The team identified analogous gene clusters across various fungal species, implying a vast, untapped reservoir of RiPPs with diverse bioactive profiles awaiting exploration. Given the emerging significance of cyclic peptides in pharmaceutical pipelines—nearly two dozen have achieved clinical approval since 2000—this fungal RiPP frontier represents a propitious field for next-generation therapeutics. Exploiting fungal biodiversity could dramatically expand the chemical space accessible for drug design, inspiring multidisciplinary collaborations across synthetic biology, medicinal chemistry, and oncology.

The researchers stress that their next milestones involve in vivo testing of asperigimycins to evaluate pharmacokinetics, bioavailability, and safety profiles within animal models. Success in these stages could pave the path towards human clinical trials and eventual incorporation into cancer treatment regimens. Concurrently, the deeper understanding of transport genes like SLC46A3 opens avenues for companion diagnostics, allowing the identification of patient subsets most likely to benefit from RiPP-based therapies, fostering personalized medicine.

As this research exemplifies the creative potential of revisiting long-dreaded microorganisms, it underscores nature’s enduring capacity to inspire innovative solutions to complex diseases. The transformation of Aspergillus flavus from an agent of historical calamity into a beacon of therapeutic hope highlights how integrative science—melding molecular biology, chemical engineering, and pharmacology—can turn ancient microbial curses into modern cures. In the words of Professor Sherry Gao, “Nature has given us this incredible pharmacy. It’s up to us to uncover its secrets.”

This pioneering work was accomplished through a collaborative effort incorporating institutions including the University of Pennsylvania School of Engineering and Applied Science, Rice University, the University of Pittsburgh, MD Anderson Cancer Center, Washington University School of Medicine, Baylor College of Medicine, and the University of Porto. Supported by a spectrum of federal and private funding bodies, the research advances not only scientific understanding but also intellectual property, with a provisional patent application filed to safeguard the novel chemical entities discovered.

As researchers continue to harness fungal RiPPs’ unexplored diversity, the implications for cancer therapy, and potentially other disease areas, become profound. This breakthrough invites the scientific community to revisit and rethink natural product-based drug discovery, especially in underexplored domains harboring biologically unprecedented molecules. The advent of asperigimycins symbolizes a leap forward, offering hope for more efficient, targeted, and less toxic cancer treatments crafted in the crucible of fungal biochemistry.

Subject of Research: Cells

Article Title: A class of benzofuranoindoline-bearing heptacyclic fungal RiPPs with anticancer activities

News Publication Date: 23-Jun-2025

Web References:
https://www.nature.com/articles/s41589-025-01946-9

References:
Based on the results presented herein, a provisional patent application (RICE.P0154US.P1) has been filed through Rice University.

Image Credits: Bella Ciervo

Keywords

Aspergillus flavus, fungal RiPPs, asperigimycins, cancer therapy, leukemia, cyclic peptides, ribosomally synthesized peptides, post-translational modifications, microtubule inhibition, SLC46A3, natural products, drug discovery